These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34923982)

  • 1. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
    Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
    BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
    Zheng J; Deng Y; Huang B; Chen X
    Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ALOX5 in non-small cell lung cancer: A potential therapeutic target associated with immune cell infiltration.
    Zhao Q; Sun Z; Pan Y; Jing Q; Li W; Wang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):311-322. PubMed ID: 37164914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of cathepsin F predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou X; Chen H; Huang D; Guan G; Ma X; Cai W; Liao J; Guan T
    Sci Rep; 2024 Jun; 14(1):13556. PubMed ID: 38866930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression and prognosis of x-ray repair cross-complementing family members in non-small cell lung cancer.
    Fan Y; Gao Z; Li X; Wei S; Yuan K
    Bioengineered; 2021 Dec; 12(1):6210-6228. PubMed ID: 34486486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.
    Hou Y; Xiang B; Yang Z; Liu J; Xu D; Geng L; Zhan M; Xu Y; Zhang B
    Int J Immunopathol Pharmacol; 2023; 37():3946320231202748. PubMed ID: 37731383
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.
    Liu X; Wu S; Yang Y; Zhao M; Zhu G; Hou Z
    Biomed Pharmacother; 2017 Nov; 95():55-61. PubMed ID: 28826097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
    Li C; Pan J; Luo J; Chen X
    BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
    Gong L; Liu Q; Jia M; Sun X
    Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.